Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XmAb541

Bispecific antibody · Immune activation, directed at claudin 6 (CLDN6) and CD3 (CD3E) · developed by Xencor

Phase 1 Most advanced trial
XNCR Developer
1 Registered trials

What is XmAb541?

XmAb541 is a bispecific antibody that binds claudin 6 (CLDN6) on tumor cells and CD3 on T-cells. By engaging both, it redirects cytotoxic T-lymphocytes to kill CLDN6-expressing tumor cells. It is being studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
claudin 6 (CLDN6), CD3 (CD3E)
Mechanism
Immune activation, directed at claudin 6 (CLDN6) and CD3 (CD3E)
Pathways
cytotoxic T-lymphocyte-mediated killing
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07593092 Phase 1 Ovarian Cancer Recruiting XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Other drugs acting on CLDN6 / CD3E

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind XmAb541

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.